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Abstract: The aim of our study was to characterize the etiology of prosthetic joint infections
(PJIs)—including multidrug-resistant organisms (MDRO)—by category of infection. A multicenter
study of 2544 patients with PJIs was performed. We analyzed the causative microorganisms according
to the Tsukayama’s scheme (early postoperative, late chronic, and acute hematogenous infections (EPI,
LCI, AHI) and “positive intraoperative cultures” (PIC)). Non-hematogenous PJIs were also evaluated
according to time since surgery: <1 month, 2–3 months, 4–12 months, >12 months. AHIs were
mostly caused by Staphylococcus aureus (39.2%) and streptococci (30.2%). EPIs were characterized by
a preponderance of virulent microorganisms (S. aureus, Gram-negative bacilli (GNB), enterococci),
MDROs (24%) and polymicrobial infections (27.4%). Conversely, coagulase-negative staphylococci
(CoNS) and Cutibacterium species were predominant in LCIs (54.5% and 6.1%, respectively) and
PICs (57.1% and 15.1%). The percentage of MDROs isolated in EPIs was more than three times
the percentage isolated in LCIs (7.8%) and more than twice the proportion found in AHI (10.9%).
There was a significant decreasing linear trend over the four time intervals post-surgery for virulent
microorganisms, MDROs, and polymicrobial infections, and a rising trend for CoNS, streptococci
and Cutibacterium spp. The observed differences have important implications for the empirical
antimicrobial treatment of PJIs.
Keywords: prosthetic joint infections; microbial etiology; classification schemes for prosthetic joint
infections; antimicrobial empirical treatment; multidrug-resistant organisms
J. Clin. Med. 2019, 8, 673 3 of 15
1. Introduction
While the risk of prosthetic infection in patients undergoing joint replacement could be considered
low (hips: 0.2–1.5%, knees: 0.4–1.5%, shoulders: 0.8–2%), the high frequency of these procedures
converts the combination of low risks into a substantial burden of infection [1]. Prosthetic joint infection
(PJI) is a devastating complication associated with major patient morbidity and high healthcare and
societal costs (recent estimated costs of 20,000–40,000 dollars per infection) [1].
Biofilm formation when microorganisms attach to the surface of prosthetic devices plays a crucial
role in the pathogenesis of PJI [2]. This poses a challenge for the diagnosis of biofilm-embedded
microorganisms, and antimicrobial therapy in biofilm-associated pathogens is of limited efficacy [3].
Antimicrobial therapy combined with surgery is required to cure PJIs [4–7]. A common
management approach is to start broad-spectrum antimicrobial agents after obtaining intraoperative
samples for culture [8,9]. The importance of adequate initial empirical antimicrobial therapy in the
outcome of infections is well-known [10] and seems to be critical in patients with PJIs treated with
debridement, antibiotics, and implant retention [11]. Vancomycin combined with a broad-spectrum
beta-lactam such as piperacillin-tazobactam has been recently studied as an initial treatment [12,13] but
has been associated with a high rate of adverse effects [13]. After the pathogen has been identified and
antimicrobial susceptibility results are available, the most effective narrow-spectrum antibiotic regimen
is selected for continuation of therapy [4–8,10]. Nevertheless, a significant number of patients (5–35%)
have negative cultures [8]. In this situation, empirical antimicrobial therapy is even more important,
but more difficult to decide on, taking into consideration that the patient will have to receive it for the
several weeks to months that it takes to cure a PJI [4,8].
Knowledge of the microbiological spectrum of PJIs is essential for guiding empirical antibiotic
therapy. There are, however, no specific recommendations for the most appropriate empirical
treatment for PJIs. We previously characterized the microbial etiology of PJI in a large cohort of
patients [14], but the causative microorganisms can vary significantly, depending on the infection
route and the time interval between index surgery and onset of symptoms, which can help guide
empirical treatment [4,8,12,15]. These differences may include the involvement of multidrug-resistant
microorganisms (MDRO), although this aspect has not been previously studied. There are several
useful classifications of PJI in different categories, namely based on the mode of acquisition and/or time
from prosthesis implantation, but none of them are universally accepted [8,16]. A good deal of what is
currently known about the microbial etiology of different categories of PJI is based on studies that
are limited by small sample sizes [11,15,17–31] and describe single-center experiences [12,15,17–24,26–
28,30–32]. Most focus on specific types of infection, [11,21,23,25,29] surgical strategies used during
treatment [22,31], or include only infections occurring within a limited period of time after prosthesis
implantation [30,33]. Consequently, the results do not adequately represent the percentages of the
different microorganisms involved in different types of infection across the full range of PJIs
Our aim was to characterize the etiology of PJIs—including MDROs—according to the category of
infection, in a large cohort of consecutive patients with PJIs. The results would enable tailoring empirical
antimicrobial therapy to the clinical situation, offering coverage of the most likely microorganisms
but narrowing the antimicrobial spectrum, which is crucial in antimicrobial stewardship program,
and potentially reducing adverse effects.
2. Methods
2.1. Setting, Study Design, and Patients
This was an ambi-directional observational study carried out at 19 hospitals in different areas
of Spain. The study was performed within the framework of the Spanish Network for Research
in Infectious Diseases (REIPI) (www.reipi.org) and included the participation of the Group for the
Study of Osteoarticular Infections (GEIO) (https://seimc.org/grupos-de-estudio/geio) belonging to the
Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). The REIPI Group for the
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Study of PJIs and the GEIO form a multicenter collaborative group of infectious disease specialists,
microbiologists, and orthopedic specialists across Spain, with extensive experience at orthopedic
infection management and had previous joint publications [14,29,34–36].
All consecutive adult patients diagnosed with PJIs between 2003 and 2012 were included. Excluded
were relapse episodes of infections that were first diagnosed before the study period.
2.2. Data Collection
This study was ambi-directional, with both prospective and retrospective data collection. Data were
first acquired from the REIPI cohort of consecutive patients with PJI who were prospectively enrolled
from 2003 through 2006. The cohort characteristics have been described elsewhere [29,34]. Apart from
clarifications concerning key variables, no further data on this prospective cohort was requested. For the
retrospective phase, data of patients who developed PJIs from 2007 through 2012 were retrospectively
collected from REIPI and other hospitals that met the criteria for participation. The three criteria
included hospitals with orthopedic surgery, the use of proper identification procedures to ensure
the inclusion of all consecutive cases diagnosed at the hospital, and that ascertainment bias was
minimized, and finally, most of the data needed to resolve queries were either available or easily
accessible. A standard case report form designed specifically for this study was used at all sites to
collect data. Data of patients with PJI were obtained from electronic databases used at most of the
participating hospitals with prospectively collected information on patients with PJI, and from the
patient’s medical records held at each hospital as required. Completed case report forms were sent
to the coordinating center for data entry, or the site investigators entered the variables directly into
the common electronic database. The coordinating center for this study was the Hospital de la Santa
Creu i Sant Pau (Barcelona, Spain). The study was approved by the Institutional Review Board at
the Hospital de la Santa Creu i Sant Pau before data collection started. All case report forms were
reviewed at the coordinating center.
2.3. Clinical Data and Definitions
The following information was collected: Patient demographics and underlying conditions,
characteristics of the arthroplasty, risk factors for MDROs, classification of the PJI, and microbiological
diagnosis. All variables were predefined to ensure standardized data collection in participating hospitals.
Individual patient data recorded included age and gender; comorbidities and immunosuppressive
therapy; the patient’s American Society of Anesthesiologists (ASA) score before the surgical procedure
(typically the arthroplasty implant) closest to the diagnosis of infection; previous exposure to antibiotics
(≥7 days) or hospitalization in the previous 90 days (≥2 days); receipt of hemodialysis, intravenous
therapy, wound care or specialized nursing care at home in the 30 days preceding the last surgical
procedure or onset of hematogenous PJI; residence in a nursing home or long-term care facility.
Information of the arthroplasty collected included: The reasons for implantation and the date
performed, site, time from admission to implantation, primary or revision arthroplasty, cemented vs.
uncemented, and the use of antibiotic-loaded bone cement. Date of diagnosis, classification of the PJI
type, and the number of cultured samples and their results were also recorded.
Cefazolin —sometimes cefuroxime, depending on the center, — was used as an antimicrobial
prophylaxis in surgery. Vancomycin or teicoplanin was used for patients who were allergic to penicillin.
Baseline comorbidities were quantified using the Charlson comorbidity score [37]. A diagnosis of PJI
was established using the 2011 Musculoskeletal Infection Society definition [38]. The microbial etiology
of PJI was established when the same organism (indistinguishable by common laboratory tests including
genus and species identification or common antibiogram) was isolated in two or more periprosthetic
cultures yielded [4]. When the diagnostic criteria for PJI were met, virulent microorganisms (such as
Staphylococcus aureus) isolated in a single periprosthetic tissue/biopsy sample were also considered
causative organisms [7]. MDRO was defined following Magiorakos et al. (acquired non-susceptibility
to at least one agent in three or more specified antimicrobial categories) [39].
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The Tsukayama scheme was used to classify PJIs. This scheme divides PJIs into four categories,
based partly on presumed mode of infection and time since surgery: [15,40] a) Early postoperative
infection (EPI): PJI diagnosed within one month of the index surgery (usually implantation of joint
prosthesis, but also later procedures performed at the arthroplasty site); b) late chronic infection (LCI):
PJIs with an insidious clinical course diagnosed >1 month after the index operation; both EPI and LCI
are considered perioperatively acquired; c) acute hematogenous infection (AHI): PJI associated with
documented or suspected antecedent bacteremia and characterized by acute onset of symptoms in
the affected joint with the prosthesis; d) positive intraoperative culture (PIC): PJI diagnosed when at
least two specimens, from a minimum of five obtained at the time of revision surgery, are positive
after culture; infection was not clinically obvious or suspected at the time of the revision [15,40].
AHI and PIC can occur any time after surgery. EPI and AHI are acute PJIs that can be treated and
potentially cured with debridement and antibiotics, without removal of the prosthesis. Another
commonly used classification scheme based only on time since index surgery classifies PJIs as early
(develops <3 months after surgery), delayed (3 to 12 or 24 months after surgery), or late (>12 or
24 months after surgery) [8,41]. This chronological framework was used to further analyse all cases of
non-hematogenous PJI.
2.4. Statistical Analysis
Medians and interquartile ranges were used to summarize continuous variables, and absolute
numbers and percentages of total samples for categorical variables. Statistical analyses were based
on differences in the percentages of causative microorganisms/groups of organisms of PJI in the
four categories of the Tsukayama scheme (EPI, LCI, AHI, PIC). The causative microorganisms
of non-haematogenous PJIs diagnosed according to time since surgery (within the first month,
in months 2/3, months 4–12, and more than 12 months after the index surgery), were also
compared. These percentages were compared using the χ2 test or Fisher’s exact test as appropriate.
To determine statistically significant linear trends in the proportions of infection caused by specific
microorganisms/groups of organisms over time the Mantel-Haenszel χ2 test for trend was used.
The data were analyzed using SPSS, version 22.0 (IBM SPSS, Chicago, IL, USA)
3. Results
Overall, 2524 episodes of PJI were diagnosed during the study period in 19 participating hospitals
located in eight of the 17 administrative regions of Spain. All were university hospitals except for one.
In 17 hospitals, they had more than 500 beds, and two had between 400 and 500 beds.
The characteristics of the patients are outlined in Table 1. Most infections occurred in hip or knee
arthroplasties; 77.2% affected primary arthroplasties. The most common reason for joint replacement
was degenerative joint disease.
LCI was the most frequent type of infection, accounting for 47.4% (1178) of cases, followed by EPI
(35.7%, 888), AHI (11.6%, 288) and PIC (5.3%).
A microbiological diagnosis was obtained in 2288 cases (90.6%) and significantly more frequently
in EPI (94.5%, 839) and AHI (92%, 256) than in LCI (89.3%, 1052) (p < 0.001).
The causative microorganisms of PJI using Tsukayama’s classification are shown in Tables 2 and 3.
Overall, coagulase-negative staphylococci (CoNS) were the most common group of microorganisms
involved in PJI (with Staphylococcus epidermidis as the most frequent species). They were more often
isolated in chronic (>50% of cases) than in acute infections. Whereas CoNS represented almost 30% of
EPIs, they were involved in less than 10% of AHI. S. aureus on the other hand, was the microorganism
most often involved in acute infection and the leading causative species of EPI and AHI. Streptococci
were significantly more common in AHI, while enterococci were more frequent in EPI than in other
categories of PJI.
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Table 1. Characteristics of patients with prosthetic joint infection diagnosed between 2003 and 2012.
Characteristic No. of Cases (n = 2524)
Median age (IQR), years 74 (13)
Female gender 1508 (59.7)
Underlying conditions
• Any comorbid condition 1594 (63.3)
• Diabetes mellitus 592 (23.5)
• Heart disease 506 (20.1)
• Chronic obstructive pulmonary disease 299 (11.9)
• Cancer 231 (9.2)
• Neurological disease 221 (8.8)
• Chronic kidney disease 195 (7.7)
• Systemic rheumatic (connective tissue) disease 175 (6.9)
• Immunosuppressive treatment 168 (6.7)
• Liver disease 164 (6.5)
• Rheumatoid arthritis 129 (5.1)
Charlson score, median (IQR) 1 (2)
Index arthroplasty site
• Hip 1244 (49.3)# Hemiarthroplasty 249 (9.9)# Total arthroplasty 995 (39.5)
• Knee 1219 (48.3)
• Shoulder 46 (1.8)
• Other 15 (0.6)
ASA score, median (IQR) 2 (1)
Indication for index arthroplasty*
• Primary joint replacement 1938 (77.2)# Osteoarthritis 1264 (52.4)# Fracture 417 (17.3)# Avascular necrosis 51 (2.1)# Rheumatoid arthritis 32 (1.3)# Tumor 31 (1.3)# Septic arthritis sequelae 12 (0.5)# Other 43 (1.8)
• Revision arthroplasty (prior joint arthroplasty) 573 (22.8)# Aseptic loosening 292 (12.1)# Infection 158 (6.6)# Dislocation 32 (1.3)# Periprosthetic fracture 25 (1)# Implant failure or fracture 13 (0.5)# Other 29 (1.2)
Unless stated otherwise, data refer to numbers (%) of patients with the indicated characteristic. ASA = American
Society of Anesthesiologists; IQR = interquartile range. * Information on indication for index arthroplasty was not
available for 112 (4.4%) procedures.
Aerobic Gram-negative bacilli (GNB), both Enterobacteriaceae and non-fermenting Gram-negative
bacilli, were much more frequently involved in EPI than in the other types of infection. Escherichia coli,
however, was isolated almost as frequently in AHI as in EPI.
Cutibacterium (formerly Propionibacterium) spp. were more common in chronic than in acute PJI,
but with a significantly higher proportion in the PIC group (15.1%) than in the LCI (6.1%).
Polymicrobial infections were much more frequent in the EPI category (27.4%) than in other
types, and MDROs (both methicillin-resistant S. aureus (MRSA) and multidrug-resistant GNB,
including extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae) were also much
more commonly isolated in EPIs than in other categories of infection. Ciprofloxacin-resistant GNB
were also more common in EPIs.
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Table 2. Aerobic Gram-positive cocci involved in prosthetic joint infections using the four categories of
the Tsukayama classification.
Microorganism or Microorganism Group
Early
Postoperative
Infections
n = 839
Acute
Hematogenous
Infections
n = 265
Late Chronic
Infections
n = 1052
Positive
Intraoperative
Cultures
n = 126
p-Value
Total no. (%)*
Staphylococcus species 505 (60.2) 122 (46) 776 (73.8) 84 (66.7) <0.001
• Coagulase-negative Staphylococci (CoNS) 236 (28.1) 23 (8.7) 573 (54.5) 72 (57.1) <0.001# Staphylococcus epidermidis 130 (15.5) 11 (4.2) 355 (33.7) 36 (28.6) <0.001# Staphylococcus lugdunensis 2 (0.2) 6 (2.3) 31 (2.9) 4 (3.2) <0.001# Staphylococcus capitis 8 (1) 0 (0) 25 (2) 2 (1.6) 0.014# Staphylococcus hominis 8 (1) 0 (0) 22 (2.1) 0 (0) 0.014# Staphylococcus warneri 5 (0.6) 0 (0) 11 (1) 3 (2.4) 0.065# Staphylococcus auricularis 2 (0.2) 0 (0) 12 (1.1) 1 (0.8) 0.048# CoNS not identified to species level 89 (10.6) 6 (2.3) 168 (16) 23 (23) <0.001
• Staphylococcus aureus 299 (35.6) 104 (39.2) 224 (21.3) 12 (9.5) <0.001
Streptococcus species 36 (4.3) 80 (30.2) 85 (8.1) 5 (4) <0.001
• Streptococcus agalactiae 8 (1) 28 (10.9) 28 (2.7) 0 (0) <0.001
• Viridans group streptococci not identified to
species level 6 (0.7) 12 (4.5) 25 (2.4) 2 (1.6) 0.002
• Streptococcus mitis group 8 (1) 5 (1.9) 16 (1.5) 2 (1.6) 0.632
• Streptococcus anginosus group 3 (0.4) 8 (3) 12 (1.1) 1 (0.8) 0.005
• Streptococcus pyogenes 10 (1.2) 5 (1.9) 1 (0.1) 0 (0) 0.003
• Streptococcus pneumoniae 0 (0) 10 (3.8) 2 (0.2) 0 (0) <0.001
• Streptococcus dysgalactiae 2 (0.2) 7 (2.6) 1 (0.1) 0 (0) <0.001
Enterococcus species 106 (12.6) 6 (2.3) 66 (6.3) 4 (3.2) <0.001
• Enterococcus faecalis 95 (11.3) 5 (1.9) 55 (5.2) 3 (2.4) <0.001
• Enterococcus faecium 7 (0.8) 1 (0.4) 5 (0.5) 0 (0.0) 0.584
* Percentages marked in bolded blue are statistically significant highest percentages in that row. Two percentages
marked in bolded blue in the same row refer to the highest percentages (both are significantly higher than the other
two percentages), but with no statistically significant differences between them.
Table 3. Microorganisms and group of microorganisms (other than aerobic Gram-positive cocci)
involved in prosthetic joint infections according to the four categories of the Tsukayama classification.
Microorganism or Microorganism Group
Early
Postoperative
Infections
n = 839
Acute
Hematogenous
Infections
n = 265
Late Chronic
Infections
n = 1052
Positive
Intraoperative
Cultures
n = 126
p-Value
Total no. (%)*
Aerobic Gram-negative bacilli 395 (47.1) 60 (22.6) 161 (15.3) 14 (11.1) <0.001
• Enterobacteriaceae 303 (36.1) 49 (18.5) 106 (10.1) 6 (4.8) <0.001# Escherichia coli 129 (15.4) 33 (12.5) 41 (3.9) 3 (2.4) <0.001# Proteus spp. 75 (8.9) 4 (1.5) 27 (2.6) 2 (1.6) <0.001# Enterobacter spp. 73 (8.7) 5 (1.9) 19 (1.8) 0 (0) <0.001# Klebsiella spp. 48 (5.7) 1 (0.4) 1 (0.4) 9 (0.9) <0.001# Morganella morganii 26 (3.1) 4 (1.5) 11 (1) 1 (0.8) =0.009# Serratia marcescens 13 (1.5) 0 (0) 6 (0.6) 0 (0) =0.028
• Non-fermenting Gram-negative bacilli 137 (16.3) 9 (3.4) 62 (5.9) 9 (7.1) <0.001# Pseudomonas spp. 128 (15.3) 8 (3) 59 (5.6) 6 (4.8) <0.001# Acinetobacter spp. 10 (1.2) 0 (0) 2 (0.2) 1 (0.8) 0.021
Aerobic Gram-positive bacilli 16 (1.9) 5 (1.9) 29 (2.8) 4 (3.2) 0.555
• Corynebacterium species 16 (1.9) 1 (0.4) 29 (2.8) 4 (3.2) 0.087# Corynebacterium striatum 9 (1.1) 0 (0) 7 (0.7) 1 (0.8) 0.321# Corynebacterium spp. without identification to species level 3 (0.4) 1 (0.4) 14 (1.3) 2 (1.6) 0.081
Anaerobic Gram-positive bacilli 19 (2.3) 3 (1.1) 73 (6.9)** 22 (17.3)** <0.001
• Cutibacterium spp. 17 (2) 3 (1.1) 64 (6.1)** 19 (15.1)** <0.001
Anaerobic Gram-positive cocci† 8 (1) 2 (0.8) 23 (2.2) 0 (0) 0.042
Anaerobic Gram-negative bacilli 12 (1.4) 1 (0.4) 8 (0.8) 0 (0) 0.182
• Bacteroides group 10 (1.1) 1 (0.3) 5 (0.4) 0 (0) 0.145
Mycobacterium species 2 (0.2) 0 (0) 8 (0.8) 0 (0) 0.183
Fungi 8 (1.5) 4 (1.5) 16 (1.5) 2 (1.6) 0.723
• Candida spp. 8 (1) 3 (1.1) 14 (1.3) 2 (1.6) 0.854
Multidrug-resistant organisms 201 (24) 29 (10.9) 82 (7.8) 6 (4.8) <0.001
• Methicillin-resistant S. aureus 92 (11) 22 (8.3) 58 (5.5) 5 (4) <0.001
• Multidrug-resistant Gram-negative bacilli 112 (13.3) 7 (2.6) 25 (2.4) 1 (0.8) <0.001
• Extended-spectrum beta-lactamase producing Enterobacteriaceae 36 (4.3) 2 (0.8) 4 (0.4) 0 (0.0) <0.001
Ciprofloxacin-resistant Gram-negative bacilli 63 (7.5) 7 (2.6) 20 (1.9) 3 (2.4) <0.001
Polymicrobial infections 230 (27.4)** 17 (6.3) 143 (13.1)** 7 (5.6) <0.001
* Percentages marked in bolded blue are the highest statistically significant percentages in that row. Two percentages
marked in bolded blue in the same row with no other marks, refer to the highest percentages (both are significantly
higher than the other two percentages), but with no statistically significant differences between them. ** The two highest
percentages in that row but with statistically significant differences between them. † Finegoldia magna 5, Parvimonas
micra 5, Peptostreptococcus anaerobius 3, Peptococcus niger 4, Peptostreptococcus not identified to species level 15.
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With respect to non-haematogenous infections, a microbiological diagnosis was obtained for
94.5%, 92.7%, 92%, and 88.2% of cases in the first month, months 2/3, 4–12 and more than 12 months
after index surgery, respectively, with a statistically significant decreasing linear trend (p < 0.001).
With respect to PJIs diagnosed in the first month after surgery (EPI according to the Tsukayama
classification) versus those diagnosed in the second or third month after surgery (also early infections
according to other common classifications) [5,36], the former were significantly more often caused by
S. aureus, enterococci, aerobic GNB (with more than twice the percentage of both Enterobacteriaceae and
non-fermenting GNB than in months 2 and 3), MDROs (both MRSA and multidrug-resistant GNB,
including ESBL-producing Enterobacteriaceae) and polymicrobial infections, and less often caused by
CoNS, streptococci, and Cutibacterium spp. (Table 4). Furthermore, infections diagnosed more than three
months after surgery were more frequently caused by CoNS, and less commonly by Enterobacteriaceae
than those diagnosed in the first two to three months after surgery. No other differences between
these four time intervals were observed. When the four periods of time after the index surgery were
considered overall, a statistically significant decreasing linear trend was observed for infections caused
by S. aureus, enterococci, Enterobacteriaceae, non-fermenting GNB (mainly Pseudomonas spp.), MDROs
(both MRSA and multidrug-resistant GNB), and polymicrobial infections (p < 0.001 in each case) and a
rising trend for infections caused by CoNS (p < 0.001), streptococci (p = 0.015) and anaerobic bacteria
(mainly Cutibacterium spp.) (p < 0.001).
Table 4. Microorganisms and groups of organisms involved in non-hematogenous prosthetic joint
infections according to time of infection after surgery (≤1 month, 2–3 months, 4–12 months, >12 months).
Microorganism or Microorganism Group
PJI within 1
Month after
Surgery
n = 844
PJI 2-3 Months
after Surgery
n = 243
PJI 4-12
Months after
Surgery
n = 277
PJI > 12
Months after
Surgery
n = 619
p-Value
Total no. (%)*
Staphylococcus species
• Coagulase-negative staphylococci 236 (28.2) ** 107 (44) ** † 167 (60.3) † 348 (56.2) <0.001# Staphylococcus epidermidis 132 (15.6) ** 68 (28) ** † 106 (38.3) † 203 (32.8) <0.001# Staphylococcus lugdunensis 2 (0.2) ** 3 (1.3) ** 10 (3.6) 22 (3.6) <0.001
• Staphylococcus aureus 301 (35.7) 60 (24.7) 60 (21.7) 108 (17.4) <0.001
Streptococcus species 36 (4.3) ** 25 (10.3) ** 14 (5.1) 49 (7.9) <0.001# Streptococcus agalactiae 8 (0.9) ** 11 (4.5) ** 6 (2.2) 10 (1.6) 0.003# Viridans group streptococci not identified to species level 6 (0.7) ** 7 (2.9) ** 2 (0.7) † 18 (2.9) † 0.003
Enterococcus species 106 (12.6) 23 (9.5) 15 (5.4) 32 (5.4) <0.001
Aerobic Gram-negative bacilli 396 (46.9) ** 50 (20.6) ** † 37 (13.4) † 37 (13.4) <0.001
• Enterobacteriaceae 303 (35.9) ** 37 (15.2) ** † 25 (9) † 48 (7.8) <0.001# Escherichia coli 129 (15.3) 12 (4.9) 10 (3.6) 21 (3.4) <0.001# Proteus spp. 75 (8.9) 7 (2.9) 7 (2.5) 14 (2.3) <0.001# Enterobacter spp. 73 (8.6) ** 11 (4.5) ** † 2 (0.7) † 6 (1) <0.001# Klebsiella spp. 48 (5.7) 2 (0.8) 4 (1.4) 3 (0.5 <0.001
• Non-fermenting Gram-negative bacilli 138 (16.4) ** 16 (6.6) ** 11 (4) 41 (6.6) <0.001# Pseudomonas spp. 128 (15.2) ** 17 (7) ** 11 (4) 35 (5.7) <0.001
Aerobic Gram-positive bacilli 16 (1.9) 3 (1.2) 7 (2.5) 23 (3.7) 0.083
Anaerobic Gram-positive bacilli 19 (2.3) ** 14 (5.7) ** 16 (5.8) 61 (9.7) <0.001
• Cutibacterium spp. 17 (2) ** 12 (4.9) ** 16 (5.8) 51 (8.2) <0.001
Anaerobic Gram-positive cocci 8 (0.9) 4 (1.6) 5 (1.8) 13 (2.1) 0.330
Anaerobic Gram-negative bacilli 12 (1.4) 2 (0.8) 1 (0.4) 5 (0.8) 0.409
Mycobacterium species 2 (0.2) 1 (0.9) 4 (1.4) 2 (0.3) 0.068
Fungi 8 (0.9) 3 (1.2) 3 (1.1) 12 (1.9) 0.418
Multidrug-resistant organisms 202 (23.9) 20 (8.2) 20 (7.2) 43 (6.9) <0.001
• Methicillin-resistant S. aureus 93 (11) 14 (5.8) 14 (5.1) 30 (4.8) <0.001
• Multidrug-resistant Gram-negative bacilli 112 (13.3) 7 (2.5) 5 (1.8) 14 (2.3) <0.001
• Extended-spectrum beta-lactamases producing Enterobacteriaceae 36 (4.3) 1 (0.4) 2 (0.7) 1 (0.3) <0.001
Ciprofloxacin-resistant Gram-negative bacilli 84 (10) 5 (2.1) 4 (1.4) 11 (1.8) <0.001
Polymicrobial infections 230 (27.2) 36 (14.7) 32 (11.1) 77 (11.1) <0.001
* Percentages marked in bolded blue are the highest statistically significant percentages in that row. Two percentages
marked in bolded blue in the same row with no other indication refer to the highest percentages (both are significantly
higher than the other two percentages) with no statistically significant differences between them. ** and † indicate
adjacent percentages with statistically significant differences between them in the same row.
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Figure 1 shows the main microorganisms/groups of organisms involved in each of the Tsukayama
categories of PJI (A) and in non-haematogenous PJIs according to time since index surgery (B).J. Clin. Med. 2019, 8, x FOR PEER  12 of 18 
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4. Discussion
Empirical antimicrobial treatment is based on a diagnosis of infection without knowing the
causative microorganism, while covering those most likely to be involved in particular clinical
situations [42]. This multice ter study, which is, to our knowledg the argest ser es to have analyzed
this question, found significant differences in the microbial etiology of different types of prosthetic joint
infection. Our results show that the choice of empirical antibiotics for early postoperative infections
(EPI) (<1 month after surgery) is the most challenging, since these infections are characterized by a
preponderance of diverse and virulent pathogens, mainly S. aureus, Enterobacteriaceae, Pseudomonas
aeruginosa and enterococci, MDROs, and polymicrobial infections. These microorganisms and groups
of organisms were isolated progressively less frequently in non-hematogenous PJIs after the first
month following index surgery, whereas a steady linear increase over time was observed for less
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virulent microorganisms, such as CoNS and Cutibacterium spp. (frequently considered commensals).
Multidrug-resistant GNB were rarely encountered in non-EPI infections, and MRSA was isolated twice
as frequently in EPIs as in LCIs. The pattern for AHI was different, with S. aureus and streptococci
together accounting for almost 70% of infections. These results could help in the selection of an
empirical antimicrobial therapy that is tailored to specific clinical situations, with coverage of the most
likely microorganisms, but the narrowest possible antimicrobial spectrum.
As in other previous series, the most commonly cultured microorganisms in PJIs belonged to the
CoNS group (with S. epidermidis the most common species) [38]. These bacteria are ubiquitous members
of the human skin microbiome and lack aggressive virulence properties overall, but nevertheless
account for the most device-associated infections, mainly because of their capacity for biofilm
production [43]. These characteristics would explain our finding of CoNS as a common cause of
perioperatively-acquired PJI, with clinical manifestations increasingly more common after the early
postoperative period, but rarely a cause of AHI. In spite of significant differences between the CoNS
species [43], we found that isolates of CoNS species behaved in a similar way, although it should be
remembered that a substantial percentage of CoNS were not identified to the species level.
As in nearly all previous series, S. aureus was the most common bacterial species found as a cause
of PJI (followed by S. epidermidis) [44,45]. S. aureus was the most frequently found causative pathogen
of AHI, probably because of its high virulence. In previous studies, PJI following S. aureus bacteremia
was observed in 30 to 40% of patients with prosthetic joints. Furthermore, non-hematogenous PJIs
caused by S. aureus most often presented early [45]; our results showed a linear percentage decrease in
S. aureus after the first month post-surgery.
Overall, streptococci and enterococcus species cause only 9% and 8% of PJIs, respectively, and are
more often involved in acute than chronic infections. However, while streptococci are found in a
noteworthy 30% of AHI (the second most common cause of this type of infection after S. aureus),
enterococci are more common in EPI, although only accounting for 13% of these infections, a similar
percentage to those observed in other studies of EPI [12,29,46].
Aerobic GNB were found in 47% of EPIs using the Tsukayama classification, and 41.1% when
considering infections that presented within 90 days of surgery. This is a high proportion, similar
to percentages observed in other recent studies of PJI diagnosed in the first 3 months after surgery
(39–42%) [11,47]. GNB have been considered an infrequent cause of PJI in the classic series, accounting
for less than 10% of cases [41], although few studies have focused specifically on the etiology of PJI
across the full range of infections, or were performed a long time ago, since when the microbiology
of PJI is likely to have changed [8,14,41]. Nevertheless, the type of infection should always be taken
into consideration. Accordingly, we observed that after the first month post-surgery, the percentage of
non-hematogenous GNB PJIs steadily declined to 13.4% after the third month, which approaches the
percentages found in the classic series.
C. acnes is a major colonizer of the human skin that has recently emerged as a significant
opportunistic pathogen able to cause implant-associated infections, typically with fewer clinical
manifestations of infection than other bacteria [48]. This may explain why it was unexpectedly found
more often in revision surgery (PIC) in our results than in other types of infection.
As in previous studies, polymicrobial PJI was much more frequently found in EPI than in any
other type [8]; the percentages of polymicrobial AHI and PIC cases were very low and the proportion
of non-hematogenous polymicrobial PJIs decreased over time after the index surgery.
MDROs, which included mainly MRSA and multidrug-resistant GNB, were isolated in almost
a quarter of EPIs, but rarely in other types of infection. Since no previous studies have studied the
involvement of MDROs, and GNB especially, in terms of the category of infection, these results should
be corroborated by other studies. Although the local epidemiology of MDROs will vary [49], our results
suggest that, overall, they are more often isolated in EPIs.
Based on our findings, some recommendations can be made for empirical antimicrobial treatment
of PJIs. The regimen for a non-hematogenous PJI diagnosed in the first month following surgery should
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cover staphylococci, including methicillin-resistant staphylococci (with vancomycin or antibiotics
with a similar spectrum, such as other glycopeptides or daptomycin) as well as Enterobacteriaceae
and P. aeruginosa (with an antipseudomonal cephalosporin such as cefepime or ceftazidime). Overall,
it seems that a broader-spectrum beta-lactam (such as piperacillin/tazobactam or a carbapenem) is not
needed because of the low proportion of anaerobes and ESBL-Enterobacteriaceae. Likewise, in patients
with non-hematogenous PJIs diagnosed in the second or third month after surgery, empirical regimens
should also include methicillin-resistant staphylococci and Enterobacteriaceae, although coverage
of P. aeruginosa may be unnecessary, and a third-generation non-antipseudomonal cephalosporin
(ceftriaxone/cefotaxime) could be used instead of cefepime/ceftazidime. For non-hematogenous PJIs
arising after the third month, empirical coverage of GNB (Enterobacteriaceae and P. aeruginosa) may
not be required, also bearing in mind that these PJIs require removal of the prosthesis and the initial
empirical therapy may not be so critical in this situation (although this issue has not so far been
studied). For hematogenous infections, empirical treatment against S. aureus, streptococci, and E. coli
(with a low percentage of multidrug-resistant Enterobacteriaceae) is recommended; coverage of MRSA
should be considered even though this pathogen represents less than 10% of cases, because of the high
mortality associated with MRSA bacteremia (which rises with inappropriate empirical therapy) [45].
Hence, a regimen including vancomycin (other glycopeptides/daptomycin) and ceftriaxone/cefotaxime
could be envisaged. Empirical treatment may be needed for PIC until antibiogram data is available
and coverage of methicillin-resistant staphylococci should be considered; it should also be borne
in mind that C. acnes is usually susceptible to penicillin [43]. Despite the undoubted importance of
rifampin and quinolones in the treatment of PJI, these agents are not recommended during the initial
treatment phase of infection [2,6]. A preoperative synovial fluid culture is helpful for identification of
the causative microorganism and determination of their antimicrobial susceptibility and, in addition,
for informing the choice of postoperative antimicrobials. This can be very useful in chronic infections;
although less so in acute infections since antimicrobial therapy is commonly started before the culture
results are available. Nevertheless, a perioperative aspiration culture has shown a moderate average
sensitivity of 68% [50].
There is at present no universally accepted classification of PJI [8,16]. The best classifications
would be useful for therapeutic decision making, such as deciding on surgical treatment (debridement
and implant retention or device removal) and starting appropriate empirical antimicrobial treatment.
Following the Tsukayama scheme, EPI and AHI can potentially be cured with debridement and implant
retention, while LCI requires prosthesis removal for cure. In the case of PIC, the surgical decision
has already been made. Furthermore, each category of infection has a specific etiological pattern
that facilitates tailored empirical treatment. LCIs presenting in months two to three and more than
three months after surgery have different microbiological characteristics (mainly based on a significant
difference in the incidence of CoNS and Enterobacteriaceae), which may allow empirical treatment to be
refined. A new category that includes the two to three month postoperative period should therefore
be considered. This new category is of further interest due to the possibility of curing PJIs without
removal of the prosthesis during this period [6,51].
The limitations of our study are mainly related to its partial retrospective design, although it
would be very difficult to collect such a large number of PJI cases with any other. The study assesses
the microbial etiology of PJIs in our country and our results may not be generalizable to other countries,
although other studies in different areas of the world have shown comparable results in many respects.
Another strength of our study is its use of a standardized definition of MDRO [39], which enables
comparisons of results with other centers. This definition of MDRO, however, has limitations in the
context of PJI, since it does not include a definition of multidrug-resistant CoNS [39]. Nevertheless,
the vast majority of clinically recovered CoNS isolates are methicillin-resistant [38], which determines
the empirical treatment of PJIs. Our study also included all consecutive patients with a diagnosis of
PJI, avoiding potential inclusion bias and guaranteeing that the various categories of infection were
adequately represented.
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Our study provides detailed, comprehensive information about the microbial etiology of different
categories of PJI. Notable differences in the causative microorganisms of these types of infection were
found, which could be useful for optimizing empirical antimicrobial therapy of PJI and for improving
the outcome of these infections. The Tsukayama classification is a useful guide for the treatment of PJI,
although an extra category specific to non-hematogenous infections presenting in the second and third
month after surgery should be considered.
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